Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

This study evaluated the molecular mechanisms, clinical efficacy, and safety of off-label therapies for male androgenetic alopecia and determined the relative efficacy of these therapies compared to topical minoxidil through a network meta-analysis.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This study found that certain off-label topical therapies, including prostaglandin analogs and polyphenols, improved hair restoration in men with androgenetic alopecia over placebo in the short term, though long-term effects are unknown.